| Name | Befotertinib |
|---|
| Description | Befotertinib (D-0316) is the third-generation EGFR tyrosine kinase inhibitor. Befotertinib can be used for the research of EGFR T790M-positive non-small cell lung cancer (NSCLC)[1]. |
|---|---|
| Related Catalog | |
| Target |
EGFR tyrosine kinase[1] |
| References |
| Molecular Formula | C29H32F3N7O2 |
|---|---|
| Molecular Weight | 567.61 |